Inflammation in dilated cardiomyopathy

Herz

Volumn 29, Issue 8, 2004, Pages 788-793

  Pankuweit, Sabine ^a   Ruppert, Volker ^a   Maisch, Bernhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Autoimmunity; Chronic myocarditis; Cross reactivity; Inflammatory cardiomyopathy; T lymphocytes; Viral infection

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE COURSE; HEART MUSCLE INJURY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MYOCARDITIS; OXIDATIVE STRESS; TREATMENT OUTCOME; VIRUS INFECTION;

ANIMALS; CARDIOMYOPATHY, DILATED; CYTOKINES; HUMANS; INFLAMMATION; MODELS, IMMUNOLOGICAL; MYOCARDITIS;

EID: 12344251548     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-004-2626-9     Document Type: Article

References (39)

1. Anandasabapathy S, Frishman WH. Innovative drug treatment for viral and autoimmune myocarditis. J Clin Pharmacol 1998;38:295-308.
2. Aretz HAT, Billingham ME, Edwards WD, et al. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol 1987;1:3-14.
3. Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart 1997;78:539-43.
4. Binah O. Cytotoxic lymphocytes and cardiac electrophysiology. J Mol Cell Cardiol 2002;34:1147-61.
5. Bowles NE, Richardson PJ, Olsen EGJ, et al. Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1986:1:1120-3.
6. Caforio AL, Mahon NJ, Tona F, et al. Circulating cardiac antibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 2002;4:411-7.
7. Calabrese F, Thiene G. Myocarditis and dilated cardiomyopathy: microbiological and molecular biological aspects. Cardiovasc Res 2003;60:11-25.
8. Call JT, Deliargyris EN, Newby LK. Focusing on inflammation in the treatment of atherosclerosis. Cardiol Rev 2004;12:194-200.
9. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420(6917):885-91.
10. Cunningham MW, Antone SM, Smart M, et al. Molecular analysis of human cardiac myosin-cross-reactive B- and T-cell epitopes of the group A streptococcal M5 protein. Infect Immun 1997;65:3913-23.
11. Felix SB, Staudt A, Dörffel WV, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 2000;36:1590-8.
12. Frangogiannis ND, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;c53:31-47.
13. Grumbach IM, Heim A, Pring-Akerblom I, et al. Adenoviruses and enteroviruses as pathogen in myocarditis and dilated cardiomyopathy. Acta Cardiol 1999;54:83-8.
14. Grunig E, Tasman JA, Kucherer H, et al. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol 1998;31:186-94.
15. Gullestad L, Aass H, Fjeld JG. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001;103:220-5.
16. Huber SA. Autoimmunity in myocarditis: relevance of animal models. Clin Immunol Immunopathol 1997;83:93-102.
17. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past to the future. Circulation 1999;99:1091-100.
18. Kishimoto C, Shioji K, Kinoshita M, et al. Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress. Int J Cardiol 2003;91:173-8.
19. Li YY, Maisch B, Rose ML, et al. Point mutations in mitochondrial DNA of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1997;29:2699-709.
20. Liu P, Martino T, Opavsky MA, et al. Viral myocarditis: balance between viral infection and immune response. Can J Cardiol 1996;12:935-43.
21. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation 2001;104:1076-82.
22. Maisch B, Hufnagel G, Schönian U, et al., for the ESETCID Investigators. The European Study of Epidemiology and Treatment of Inflammatory Cardiac Disease (ESETCID). Eur Heart J 1995;516:172-5.
23. Maisch B, Portig I, Ristić AD, et al. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus - a status report. Herz 2000;25:200-9.
24. Maisch B, Schönian U, Crombach M, et al. Cytomegalovirus associated inflammatory heart muscle disease. Scand J Infect Dis 1993;88:135-48.
25. Malkiel S, Kuan AP, Diamond B. Autoimmunity in heart disease: mechanisms and genetic susceptibility. Mol Med Today 1996;2:336-42.
26. Malkiel S, Liao L, Cunningham MW, et al. T-cell-dependent antibody response to the dominant epitope of streptococcal polysaccharide, N-acetyl-glucosamine, is cross-reactive with cardiac myosin. Infect Immunol 2000;68:5803-8.
27. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002;29:988-98.
28. Mason JW. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res 2003;60:5-10.
29. Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C infection. Circulation 1995;92:2519-25.
30. McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000;342:690-5.
31. Müller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000;101:385-91.
32. Pankuweit S, Baandrup U, Moll R, et al. Prevalence of parvovirus B 19 genome in endomyocardial biopsy specimen. Hum Pathol 2003;34:80-6.
33. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996;93:841-2.
34. Schwimmbeck PL, Badorff C, Schultheiss HP, et al. Transfer of human myocarditis into severe combined immundeficiency mice. Circ Res 1994;75:156-64.
35. Seder R, Gazzinelli AP, Sher A, et al. Interleukin-12 acts directly on CD4+ T cells to enhance priming for IFN-γ production and diminishes interleukin-4 inhibition of such priming. Proc Natl Acad Sci U S A 1993;90:10188-92.
36. Towbin JA, Bowles NE. The failing heart. Nature 2002;415:227-33.
37. Wessely R, Klingel K, Santana LF, Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J Clin Invest 1998;102:1444-53.
38. Why HJ, Meany BT, Richardson PJ, et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994;89:2582-9.
39. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: 2-year follow-up results.Circulation 2001;104:39-45.